(Veru) Shares of Veru Inc. rose more than 35% in premarket on Wednesday after FDA said it was due for an emergency authorization of Sabizabulin in hospitalized COVID-19 Patients.
FDA agreed with Veru that the company did not need to conduct further efficacy studies or generate additional safety data to support its request for emergency use authorization.
Following the recommendation, Veru will seek a EUA application in the second quarter of this year.
Veru says it has initiated talks with government agencies in the US and across the world for purchase deals of Sabizabulin.
VERU: NASDAQ is up +35.56% in premarket.
